HIV/AIDS Clinical Trials

Showing 141-160 of 3,256 trials

Resilient HIV Implementation Science With SGM Youths Using Evidence

NCT06350682

The Resilient HIV Implementation Science with SGM Youths using Evidence (RISE) Clinical Research Center will use a Type 2 hybrid-effectiveness-implementation study to evaluate the effectiveness and implementation of HMP, a youth-tailored digital health platform. It is hypothesized that SGM youths in the HMP intervention group will demonstrate improved PrEP initiation and viral load suppression over 12 months compared to the delayed HMP group.

Hiv

University of Maryland, Baltimore1,500 participantsStarted Mar 2026

COMPLETEDPhase 1

Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults

NCT05423418

This study will evaluate the safety and tolerability (including reactogenicity) of candidate vaccine A244/B.63521 with Army Liposome Formulation (ALF) mixed with the saponin QS-21(Quillaja saponaria-21) (ALFQ) adjuvant. The purpose of this phase I randomized, double-blind clinical trial is to optimize vaccine adjuvant ALFQ dosing by assessing safety, reactogenicity, and immunogenicity. Safety and tolerability will be assessed with both clinical and laboratory monitoring. Sixty human immunodeficiency virus (HIV) negative participants will be enrolled to one of three arms. Vaccinations via intramuscular (IM) injection will occur at months 0, 1, and 2. All participants will receive A244 and B.63521 (300 micrograms of each). In addition, Arm 1 will receive 200 micrograms of ALFQ. Arm 2 will receive 100 micrograms of ALFQ. Arm 3 will receive 50 micrograms of ALFQ.

Human Immunodeficiency Virus (HIV)AIDS Virus

U.S. Army Medical Research and Development Command65 participantsStarted Sep 2022

Silver Spring, Maryland, United States

Resilient HIV Implementation Science With SGM Youths Using Evidence

Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults

Related Searches

PrEP Affect Regulation Treatment Innovation

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

Adaptation of an Intervention Addressing Barriers to PrEP Use Among Pregnant Women in Zimbabwe

Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)

MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo

Mobile Phone Messaging to Improve Reproductive Health for Women Living With HIV in Kenya (Mobile WACh Empower)

Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS5 Rwanda

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

Strategies to AchieVe Viral Suppression for Youth With HIV

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

Safety Study of MucoCept-CVN

In This toGether R01

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

The DC Cohort Longitudinal HIV Status Neutral Study

Long-Acting Injectable HIV PrEP PROs